News | November 15, 2011

Cangrelor Effective as Bridge for Patients Requiring Bypass Surgery

November 15, 2011 — Data from the BRIDGE clinical trial demonstrate that intravenous use of the drug cangrelor was effective at maintaining platelet inhibition in patients on thienopyridines who required bypass surgery. Trial results were presented at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

Thienopyridines are antiplatelet medications that work to prevent blood clotting and improve circulation. Though they are among the most widely prescribed medications, their use can be complicated by the unanticipated need for surgery. Despite increased risk of thrombosis, guidelines recommend discontinuing thienopyridines 5 – 7 days prior to surgery to minimize bleeding. 

In the BRIDGE trial, researchers sought to determine whether the investigational drug cangrelor could be used as a “bridge” between discontinuing thienopyridines and surgery.

BRIDGE is a prospective, randomized double-blind, placebo-controlled, multi-center trial in 210 patients with acute coronary syndrome (ACS) or treated with a coronary stent on a thienopyridine. All patients were awaiting coronary artery bypass grafting (CABG) to receive either cangrelor or placebo after an initial open-label, dose-finding phase. After thienopyridines were stopped, patients were administered cangrelor or a placebo for at least 48 hours, which was then discontinued 1 – 6 hours prior to surgery.

The primary efficacy endpoint of the trial was platelet reactivity (measured in P2Y12 Reaction Units [PRU]), assessed daily with the VerifyNow P2Y12 assay. The main safety endpoint was excessive CABG-related bleeding.

The dose of cangrelor determined in the open-label stage was 0.75 µg/kg/min. In the randomized phase, a greater proportion of patients treated with cangrelor had low levels of platelet reactivity throughout the entire treatment period compared with placebo (primary endpoint, PRU<240: 98.8 percent vs. 19.0 percent; odds ratio: 353, 95 percent confidence interval: 45.6-2728, p<0.001). Excessive CABG-related bleeding occurred in 11.8 percent vs. 10.4 percent in the cangrelor and placebo groups, respectively (p=0.76). There were no significant differences in major bleeding prior to CABG, although minor bleeding was numerically higher with cangrelor.

“Results of the BRIDGE trial indicate that in patients on thienopyridines who undergo cardiac surgery, intravenous cangrelor provides effective maintenance of platelet inhibition with no apparent increase in major bleeding, despite numerically higher rates of minor bleeding prior to surgery, which however were mostly attributed to ecchymosis at the site of venipuncture. Larger patient samples are needed to more definitively assert the safety and effectiveness of cangrelor bridging therapy to surgery,” said Dominick J. Angiolillo, M.D., Ph.D., the lead investigator of the trial. Angiolillo is an associate professor of medicine and director of cardiovascular research at the University of Florida College of Medicine in Jacksonville, Fla.

The BRIDGE trial is funded by The Medicines Company.

Angiolillo reports receiving honoraria for lectures from Bristol Myers Squibb, Sanofi-Aventis, Eli Lilly Co., and Daiichi Sankyo, Inc.;  honoraria for consulting/advisory board from Bristol Myers Squibb, Sanofi-Aventis, Eli Lilly Co., Daiichi Sankyo, Inc., The Medicines Company, Portola Pharmaceuticals, Novartis, Arena Pharmaceuticals, Accumetrics, Medicure, Evolva, and Abbott Vascular; and research grants (paid to institution) from GlaxoSmithKline, Otsuka, Accumetrics, Eli Lilly Co., Daiichi Sankyo, Inc., The Medicines Company, Portola Pharmaceuticals, Schering-Plough, AstraZeneca, Johnson & Johnson, Bristol-Myers Squibb and Sanofi-Aventis.

For more information:

Related Content

Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Prescribing Patterns Change Following Direct Marketing Restrictions
News | Pharmaceuticals | May 05, 2017
A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found...
EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals | April 03, 2017
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other...
synthetic HDL-C injection, cholesterol, arterial plaque, heart attack patients, CARAT trial, ACC.17, clinical study
News | Pharmaceuticals | March 29, 2017
Injection of a novel form of synthetic high-density lipoprotein cholesterol (HDL-C), or good cholesterol, into the...
Overlay Init